In addition to the effects in patients with cutaneous T-cell lymphoma, HDAC inhibitors appear to be active in Hodgkin's lymphoma and other haematological malignancies (Duvic et al, 2007). The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.